ClinicalTrials.gg
CompletedNCT02701647Updated Nov 22, 2019Results posted

Effects of Combined rTMS and Treadmill Training in People With Parkinson's Disease

An interventional study of Repetitive transcranial magnetic stimulation (rTMS) and Treadmill training in Parkinson's Disease, sponsored by The Hong Kong Polytechnic University. Completed at 1 site in Hong Kong. Open to participants aged 40 Years to 70 Years. Per ClinicalTrials.gov, last updated 2019-11-22.

Sponsored by The Hong Kong Polytechnic University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
51
Allocation
Randomized
Ages
40 Years to 70 Years
Sex
All
01

Study summary

The purpose of this study is to investigate whether the beneficial effect of treadmill training on people with Parkinson's disease can be enhanced by high- and low-frequency repetitive transcranial magnetic stimulation (rTMS).

Read the detailed description

This is a randomised placebo-controlled trial. Fifty-one participants with Parkinson's disease (PD) will be recruited from the Hong Kong PD association, a self-help group and movement disorders clinic of 3 local hospitals. Written informed consent in accordance with the Declaration of Helsinki will be obtained from all participants. Eligible participants will be randomly assigned into one of the three groups: 1Hz-TT, 25Hz-TT, and sham-TT upon recruitment. Randomisation will be generated by a computer program and group assignment will be blinded to both participants and assessor. Participant will receive either 1-Hz, 25-Hz, or sham rTMS which will last for about 20 minutes followed by 30 minutes treadmill walking training for 12 sessions, 4 times per week for 3 weeks. All assessments will be conducted 1 week before intervention and 1 day after completion of intervention, after 1-month training and at 3-month post training.

The sample size calculation is based on the significant findings of the gait speed reported by Yang et al (2013). A two-way repeated measures ANOVA design with between-subject group effect (3 levels) and within-subject time effect (4 levels) determines that 15 subjects per group are required to achieve 85% power to test the interaction effect between groups and time effect with a 5% significance level and the effect size is 0.2. By assuming 10% dropout rate, 17 subjects will be required per group.

02

Conditions studied

  • Parkinson's Disease

Browse trials for

Keywords

  • Transcranial Magnetic Stimulation
  • metaplasticity
  • gait training
03

In context

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,097 are open to participants now.

This study's enrollment of 51 is above the median of 40 across 3,365 interventional studies indexed under Parkinson Disease.

Browse Parkinson Disease studies →

Lead sponsor

The Hong Kong Polytechnic University is the lead sponsor of 676 studies on the registry; 254 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with idiopathic Parkinson's disease by a neurologist
  • had been stable on anti-Parkinsonian medication
  • able to walk independently for 30 meters

Exclusion criteria

Exclusion Criteria:

  • severe co-morbidity that may interfere with their ability to participate including significant orthopaedic or rheumatological conditions or disorders of peripheral nervous systems that may interfere with mobility or balance performance
  • a diagnosis of neurological disease other than PD
  • a history of psychiatric disorders
  • the impossibility of inducing motor evoked potentials (MEPs)
  • a score of less than 24 on the Mini-Mental State Examination
  • contraindication to TMS including personal or family history of seizure disorder, metal in the head, implants of medical devices such as cardiac pacemakers or medical pumps, females subjects who are pregnant, a history of neurosurgery
  • subjects with irrepressible tremor and / or dyskinesia
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
51 participants (actual)

Study arms

  • Experimental
    25Hz-TT

    Participants will receive 4s train of 25-Hz rTMS pulses with 50s inter-train interval, with an intensity of 80% resting motor threshold (RMT). Participant will receive a total of 600 rTMS pulses in 6 minutes for each hemisphere and a total of 1200 pulses followed by 30 minutes of treadmill training.

    Device: Repetitive transcranial magnetic stimulation (rTMS) · Other: Treadmill training

  • Experimental
    1Hz-TT

    Participants will receive a total of 600 1-Hz rTMS pulses in 10 minutes for each hemisphere and a total of 1200 pulses ,with an intensity of 80% RMT, followed by 30 minutes of treadmill training.

    Device: Repetitive transcranial magnetic stimulation (rTMS) · Other: Treadmill training

  • Sham comparator
    Sham-TT

    Sham rTMS will be applied over the same site as for real rTMS, however, with the cable of the coil disconnected. Another figure-of-eight coil using the same stimulation parameters (intensity, time, and frequency) as per 25Hz-TT group will be placed posterior to the subject's neck with the handle pointing backward to produce the same clicking sound effect. Sham rTMS will be followed by 30 minutes of treadmill training.

    Device: Repetitive transcranial magnetic stimulation (rTMS) · Other: Treadmill training

Interventions

  • DeviceRepetitive transcranial magnetic stimulation (rTMS)

    Repetitive TMS (rTMS) is a painless and non-invasive technique for activation of cerebral cortex based on the principle of electromagnetic induction of an electric field in the brain. rTMS will be delivered to the scalp over the leg area of the bilateral motor cortex by using a Magstim Rapid magnetic stimulator. (Magstim Company, Whitland, UK) and 90 mm double cone coil.

  • OtherTreadmill training

    Participants will proceed to 30 minute of treadmill training after rTMS. A safety harness without body weight support will be provided. 80% of participant's over ground maximum walking speed will be halved and used for warm-up. After warming up, walking speed will be increased by 0.2 km/h every 5 minutes. Progression will be given if patients could tolerate the belt speed with appropriate step length and walk with good stability for 5 minutes. Participants will maintain the maximum speed achieved for the rest of the session or adjusted as needed. Positive verbal feedback will be given to encourage large strides and upright posture during training. The participants will be instructed to walk on treadmill without holding onto the handrails if possible. Participants will perform warm up and cool down exercise to minimize training related-injury.

06

What researchers measure

Primary outcomes

  1. Fastest Walking Speed

    Each participant is instructed to walk for 14 meters at their fastest walking speed for three trials. The time taken for the middle 10 meter was recorded. The average of three trials is used for analysis.

    Time frame: Baseline, 1 day post-intervention, 1 month post-intervention, 3 month post-intervention

Secondary outcomes

  1. Timed-Up-and-Go Test (iTUG)

    Participants are instructed to stand up from a chair and walk for 7 meters walkway and return back to the chair turn around and sit down. Time and gait parameters during TUG were captured by the valid and reliable APDM system, which is a wearable gait and balance analysis system.

    Time frame: Baseline, 1 day post-intervention, 1 month post-intervention and 3 months post-intervention

  2. the Motor Section of Movement Disorders Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS III)

    MDS-UPDRS III is a valid and reliable clinical test, will be used to evaluate severity of motor symptoms of PD. There are total of 27 items including tremor, rigidity, bradykinesia, postural instability and gait performance. Each item scores from 0-4, with 0 indicates no disability and 4 maximum disabled with total score(s) ranges from 0 to 132.

    Time frame: Baseline, I day post-intervention, 1 month post-intervention and 3 months post-intervention

  3. Walking Distance in a 2 -Minute Walk Test

    The 2 minute walk test will be conducted along a 20 m x 2 m hallway. A line is marked at each end of the walkway to indicate where the person is to turn. Participants will be instructed to " walk as far as possible in 2 minutes". They will be given standardised encouragement at 60 and 90 seconds during walk. Distance walked will be recorded to the nearest meter.

    Time frame: Baseline, 1 day post-intervention, 1 month post-intervention and 3 months post-intervention

  4. Mini Balance Evaluation Systems Test Scores

    Balance performance of participants will be assessed in 4 domains namely anticipatory postural adjustments, postural responses, sensory orientation and gait stability. Each item is rated from 0-2 with a total scores of 28. The Total scores range from 0-28, with higher scores indicate better dynamic balance.

    Time frame: Baseline, 1 day post-intervention, 1 month post-intervention and 3 months post-intervention

  5. Dual-task Timed-Up-and-Go Test (DT-TUG)

    For DT-TUG, participants were instructured to repeat the TUG procedure while performing a serial three substraction. Time taken to complete DT-TUG and accuracy of digital counting was recorded. One practice trial was given prior to both TUG and DT-TUG testing and average performance of three trials was used for analysis.

    Time frame: Baseline, 1 day post-intervention, 1 month post-intervention, 3 month-post intervention

Other outcomes

  1. Cortical Silent Period

    Ten suprathreshold TMS stimuli (i.e. 130% RMT) will be delivered while participant performing a 20% isometric maximal contraction of Tibialis Anterior of the more affected side. Cortical silent period (CSP) measures the duration of interruption of electromyography (EMG) activity in the contracting muscle produced by TMS. CSP duration will be determined as the period between the onset of MEP and the return of baseline EMG activity measured 50 ms before the TMS stimulus.

    Time frame: Baseline, 1 day post-intervention, 1 month post-intervention and 3 months post-intervention

  2. Gradient of the Recruitment Curve ( Also Known as Stimulus-response Curve)

    TMS stimuli will be applied at 10% steps between 100% to 160% RMT. 10 stimuli will be delivered at each intensity. Peak to peak amplitude of 10 motor-evoked potentials (MEPs) at each stimulus intensity will be averaged offline.The cut-off intensity is set at 75% of maximum stimulator output due to discomfort perceived by majority of the participants. MEPs will be normalised with the maximal muscle action potential (MMax), which is determined by supramaximal electrical stimulation of the fibular nerve. A scatter graph will be generated with the average amplitude of MEPs as a function of stimulation intensity. The linear trend will be added to generate the linear recruitment curve slope.

    Time frame: Baseline, 1 day post-intervention, 1 month post-intervention and 3 months post-intervention

  3. Short-interval-intracortical Inhibition

    Short-interval-intracortical inhibition (SICI) is another measure of cortical inhibition. In a paired- pulse TMS paradigm, a test pulse will be adjusted to produce MEP of at least 0.5 millivolts which will be delivered preceded by a brief conditioned pulse set at a lower intensity of 80% RMT with inter-stimulus interval of 2 milliseconds. Two stimulators connected via a Bistim module ( Magstim Co.,Whitland, UK) will be used in this test. Ten conditioned MEPs and unconditioned MEPs will be obtained in a random order and were averaged for each condition. SICI is expressed as percentage of unconditioned test MEP amplitude.

    Time frame: Baseline, 1 day post-intervention, 1 month post-intervention and 3 months post-intervention

07

Results

Posted Oct 31, 2019

Participant flow

Participant flow — Overall Study
Milestone25-Hz rTMS1-Hz rTMSSham rTMS
Started171717
Completed171716
Not completed001

Outcome measures

PrimaryFastest Walking Speed

Each participant is instructed to walk for 14 meters at their fastest walking speed for three trials. The time taken for the middle 10 meter was recorded. The average of three trials is used for analysis.

Time frame:
Baseline, 1 day post-intervention, 1 month post-intervention, 3 month post-intervention
Reported as:
Mean · cm/s
Fastest Walking Speed
cm/s25-Hz rTMS1-Hz rTMSSham rTMS
Baseline149.5 ± 24.7153.1 ± 27.3156.1 ± 30.2
1 day Post intervention164.3 ± 26.3167.3 ± 34.0160.7 ± 33.3
1 month post intervention167.8 ± 26.4170.6 ± 35.6164.6 ± 32.3
3 month post intervention163.2 ± 31.0169.9 ± 38.7156.7 ± 28.0
SecondaryTimed-Up-and-Go Test (iTUG)

Participants are instructed to stand up from a chair and walk for 7 meters walkway and return back to the chair turn around and sit down. Time and gait parameters during TUG were captured by the valid and reliable APDM system, which is a wearable gait and balance analysis system.

Time frame:
Baseline, 1 day post-intervention, 1 month post-intervention and 3 months post-intervention
Reported as:
Mean · seconds
Timed-Up-and-Go Test (iTUG)
seconds25Hz-TT1Hz-TTSham-TT
Baseline20.8 ± 4.018.3 ± 2.519.3 ± 2.5
1 day Post intervention18.4 ± 2.817.1 ± 2.718.0 ± 2.1
1 month post intervention17.7 ± 2.917.1 ± 2.317.9 ± 1.8
3 month post intervention17.9 ± 2.816.6 ± 2.318.4 ± 2.1
Secondarythe Motor Section of Movement Disorders Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS III)

MDS-UPDRS III is a valid and reliable clinical test, will be used to evaluate severity of motor symptoms of PD. There are total of 27 items including tremor, rigidity, bradykinesia, postural instability and gait performance. Each item scores from 0-4, with 0 indicates no disability and 4 maximum disabled with total score(s) ranges from 0 to 132.

Time frame:
Baseline, I day post-intervention, 1 month post-intervention and 3 months post-intervention
Reported as:
Mean · score on a scale
the Motor Section of Movement Disorders Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS III)
score on a scale25-Hz rTMS1-Hz rTMSSham rTMS
Baseline27.9 ± 10.527.1 ± 9.629.7 ± 10.6
1 day Post intervention19.9 ± 8.522.2 ± 7.527.9 ± 9.0
1 month post intervention20.8 ± 8.922.5 ± 7.327.9 ± 10.1
3 month post intervention22.5 ± 10.121.9 ± 7.827.3 ± 8.0
SecondaryWalking Distance in a 2 -Minute Walk Test

The 2 minute walk test will be conducted along a 20 m x 2 m hallway. A line is marked at each end of the walkway to indicate where the person is to turn. Participants will be instructed to " walk as far as possible in 2 minutes". They will be given standardised encouragement at 60 and 90 seconds during walk. Distance walked will be recorded to the nearest meter.

Time frame:
Baseline, 1 day post-intervention, 1 month post-intervention and 3 months post-intervention
Reported as:
Mean · meter
Walking Distance in a 2 -Minute Walk Test
meter25Hz-TT1Hz-TTSham-TT
Baseline147.4 ± 29.8144.7 ± 31.3148.7 ± 25.0
1 day post intervention160.4 ± 28.0164.9 ± 29.8157.3 ± 31.7
1 month post intervention166.3 ± 29.7167.9 ± 29.7157.9 ± 29.7
3 month post intervention163.1 ± 30.7166.8 ± 31.2160.5 ± 28.9
SecondaryMini Balance Evaluation Systems Test Scores

Balance performance of participants will be assessed in 4 domains namely anticipatory postural adjustments, postural responses, sensory orientation and gait stability. Each item is rated from 0-2 with a total scores of 28. The Total scores range from 0-28, with higher scores indicate better dynamic balance.

Time frame:
Baseline, 1 day post-intervention, 1 month post-intervention and 3 months post-intervention
Reported as:
Mean · score on a scale
Mini Balance Evaluation Systems Test Scores
score on a scale25Hz-TT1Hz-TTSham-TT
Baseline21.5 ± 3.421.8 ± 2.721.7 ± 2.8
1 day post intervention24.2 ± 2.523.8 ± 2.722.4 ± 2.2
1 month post intervention23.8 ± 2.823.5 ± 2.522.8 ± 2.5
3 month post intervention23.4 ± 3.024.1 ± 2.623.0 ± 2.4
SecondaryDual-task Timed-Up-and-Go Test (DT-TUG)

For DT-TUG, participants were instructured to repeat the TUG procedure while performing a serial three substraction. Time taken to complete DT-TUG and accuracy of digital counting was recorded. One practice trial was given prior to both TUG and DT-TUG testing and average performance of three trials was used for analysis.

Time frame:
Baseline, 1 day post-intervention, 1 month post-intervention, 3 month-post intervention
Reported as:
Mean · seconds
Dual-task Timed-Up-and-Go Test (DT-TUG)
seconds25-Hz rTMS1-Hz rTMSSham rTMS
Baseline27.9 ± 8.824.0 ± 7.025.5 ± 5.6
1 day Post intervention23.1 ± 5.621.1 ± 5.223.4 ± 4.0
1 month post intervention21.8 ± 6.020.6 ± 4.723.9 ± 3.9
3 month post intervention22.3 ± 6.020.3 ± 4.623.9 ± 3.9
Other pre-specifiedCortical Silent Period

Ten suprathreshold TMS stimuli (i.e. 130% RMT) will be delivered while participant performing a 20% isometric maximal contraction of Tibialis Anterior of the more affected side. Cortical silent period (CSP) measures the duration of interruption of electromyography (EMG) activity in the contracting muscle produced by TMS. CSP duration will be determined as the period between the onset of MEP and the return of baseline EMG activity measured 50 ms before the TMS stimulus.

Time frame:
Baseline, 1 day post-intervention, 1 month post-intervention and 3 months post-intervention
Reported as:
Mean · milliseconds
Cortical Silent Period
milliseconds25-Hz rTMS1-Hz rTMSSham rTMS
Baseline176.5 ± 50.0164.6 ± 39.8183.9 ± 38.9
1 day Post intervention194.4 ± 53.2180.6 ± 39.1175.1 ± 46.6
1 month post intervention190.1 ± 54.5160.1 ± 41.1189.2 ± 37.6
3 month post intervention175.9 ± 43.2154.6 ± 46.0182.9 ± 35.0
Other pre-specifiedGradient of the Recruitment Curve ( Also Known as Stimulus-response Curve)

TMS stimuli will be applied at 10% steps between 100% to 160% RMT. 10 stimuli will be delivered at each intensity. Peak to peak amplitude of 10 motor-evoked potentials (MEPs) at each stimulus intensity will be averaged offline.The cut-off intensity is set at 75% of maximum stimulator output due to discomfort perceived by majority of the participants. MEPs will be normalised with the maximal muscle action potential (MMax), which is determined by supramaximal electrical stimulation of the fibular nerve. A scatter graph will be generated with the average amplitude of MEPs as a function of stimulation intensity. The linear trend will be added to generate the linear recruitment curve slope.

Time frame:
Baseline, 1 day post-intervention, 1 month post-intervention and 3 months post-intervention
Reported as:
Mean · millivolts / % maximum stimulator output
Gradient of the Recruitment Curve ( Also Known as Stimulus-response Curve)
millivolts / % maximum stimulator output25-Hz rTMS1-Hz rTMSSham rTMS
Baseline0.51 ± 0.300.53 ± 0.390.61 ± 0.32
1 day Post intervention0.58 ± 0.360.64 ± 0.370.52 ± 0.40
1 month post intervention0.70 ± 0.570.63 ± 0.300.59 ± 0.43
3 month post intervention0.74 ± 0.470.70 ± 0.410.58 ± 0.45
Other pre-specifiedShort-interval-intracortical Inhibition

Short-interval-intracortical inhibition (SICI) is another measure of cortical inhibition. In a paired- pulse TMS paradigm, a test pulse will be adjusted to produce MEP of at least 0.5 millivolts which will be delivered preceded by a brief conditioned pulse set at a lower intensity of 80% RMT with inter-stimulus interval of 2 milliseconds. Two stimulators connected via a Bistim module ( Magstim Co.,Whitland, UK) will be used in this test. Ten conditioned MEPs and unconditioned MEPs will be obtained in a random order and were averaged for each condition. SICI is expressed as percentage of unconditioned test MEP amplitude.

Time frame:
Baseline, 1 day post-intervention, 1 month post-intervention and 3 months post-intervention
Reported as:
Mean · percentage of Unconditioned MEPs
Short-interval-intracortical Inhibition
percentage of Unconditioned MEPs25-Hz rTMS1-Hz rTMSSham rTMS
Baseline56.4 ± 27.049.4 ± 24.162.2 ± 33.1
1 day Post intervention44.4 ± 23.051.4 ± 28.276.5 ± 49.8
1 month post intervention42.0 ± 26.962.6 ± 31.789.8 ± 62.9
3 month post intervention50.8 ± 22.860.7 ± 39.274.3 ± 30.2

Adverse events

Collected over during intervention, at 1 day post-intervention,1 month post-intervention and at 3 month post-intervention. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
25-Hz rTMS0/17 (0%)0/17 (0%)0/17 (0%)
1-Hz rTMS0/17 (0%)0/17 (0%)0/17 (0%)
Sham rTMS0/16 (0%)0/16 (0%)0/16 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)25-Hz rTMS1-Hz rTMSSham rTMSTotal
<=18 years0000
Between 18 and 65 years13111135
>=65 years46515
Age, Continuous
Age, Continuous(years)25-Hz rTMS1-Hz rTMSSham rTMSTotal
Mean62.7 ± 6.862.1 ± 5.762.1 ± 5.762.3 ± 6.0
Sex: Female, Male
Sex: Female, Male(Participants)25-Hz rTMS1-Hz rTMSSham rTMSTotal
Female78924
Male109726
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)25-Hz rTMS1-Hz rTMSSham rTMSTotal
Count of participants———0
Region of Enrollment
Region of Enrollment(participants)25-Hz rTMS1-Hz rTMSSham rTMSTotal
Hong Kong17171650
Disease duration (no. of years of diagnosis of PD)
Disease duration (no. of years of diagnosis of PD)(years)25-Hz rTMS1-Hz rTMSSham rTMSTotal
Mean5.2 ± 3.47.5 ± 4.96.9 ± 3.36.5 ± 4.0
daily levodopa equivalent dose
daily levodopa equivalent dose(mg/day)25-Hz rTMS1-Hz rTMSSham rTMSTotal
Mean484.2 ± 336.4512.5 ± 359.9493.3 ± 523.9496.8 ± 404.2
08

Study locations

1 site
  • Rehabilitation Sciences
    Hong Kong, 852, Hong Kong
09

References and documents

Publications

  • Yang YR, Tseng CY, Chiou SY, Liao KK, Cheng SJ, Lai KL, Wang RY. Combination of rTMS and treadmill training modulates corticomotor inhibition and improves walking in Parkinson disease: a randomized trial. Neurorehabil Neural Repair. 2013 Jan;27(1):79-86. doi: 10.1177/1545968312451915. Epub 2012 Jul 10. PubMed 22785003 ↗

Study documents

  • Protocol and statistical analysis plan · Dec 22, 2015

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Yes — Data will be shared with researcher who provide a methodologically sound proposal

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Beginning 3 months and ending 3 years following article publication

Access criteria: request through email

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 22, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02701647
Responsible party
Sponsor
First posted
Mar 8, 2016
Start date
Oct 2016
Primary completion
Dec 2018
Completion
May 2019
Results posted
Oct 31, 2019
Last update
Nov 22, 2019

Study contacts

Margaret Mak, PhD
principal investigator · The Hong Kong Polytechnic University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion